- Which of the following medications, which acts by inhibiting voltage-gated sodium channels, is most likely responsible for this life-threatening dermatologic reaction?
Answer: Lamotrigine
Lamotrigine is an antiepileptic and mood-stabilizing drug whose mechanism involves blockade of voltage-gated sodium channels. It carries a black box warning for potentially life-threatening rashes, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The risk is highest when the initial dose is high or the dose is escalated too rapidly, which is why a slow titration schedule is crucial.
- This adverse effect is a well-known complication of medications that increase the synaptic concentration of which neurotransmitter?
Answer: Serotonin
Sertraline is a selective serotonin reuptake inhibitor (SSRI). SSRIs work by blocking the presynaptic serotonin transporter (SERT), leading to increased levels of serotonin in the synaptic cleft. Stimulation of various serotonin receptors, particularly 5-HT2 and 5-HT3, is responsible for the common side effect of sexual dysfunction, including decreased libido, delayed ejaculation, and anorgasmia.
- A 56-year-old woman with chronic neuropathic pain is switched from morphine to methadone for better analgesia. Two days later she is found unresponsive with shallow breathing. In the emergency department, she is given 0.4 mg IV naloxone, which briefly arouses her, but she again becomes apneic within 30 minutes. Repeated doses of naloxone are required over the next 8 hours. Which pharmacokinetic property of methadone best explains the need for prolonged antidote administration?
Answer: Extensive tissue redistribution resulting in a large volume of distribution that sustains plasma levels
When you encounter a question about prolonged opioid toxicity requiring repeated antidote doses, focus on pharmacokinetic properties that affect drug persistence in the body.
Methadone has unique pharmacokinetic characteristics that distinguish it from other opioids like morphine. The key issue here is methadone's exceptionally large volume of distribution (Vd), which results from extensive tissue redistribution. Methadone is highly lipophilic and accumulates in fatty tissues, muscle, and organs like the liver. This creates a large reservoir of drug that slowly redistributes back into the plasma, maintaining therapeutic (or toxic) levels long after administration. The elimination half-life of methadone ranges from 8-59 hours (average 22 hours), much longer than morphine's 2-4 hours. This explains why naloxone's effects (half-life ~1 hour) wear off while methadone continues redistributing from tissues back into circulation, requiring repeated antidote doses.
Option B is incorrect because methadone actually has a low hepatic extraction ratio and undergoes primarily hepatic metabolism, not rapid clearance. Option C misrepresents methadone's elimination - it's metabolized hepatically, not excreted unchanged renally, and μ-receptor blockade doesn't affect renal excretion. Option D contradicts methadone's actual pharmacokinetics - it has a long, not short, elimination half-life.
Remember: For USMLE Step 1, associate methadone with prolonged toxicity due to tissue accumulation and slow redistribution. This same principle explains why methadone withdrawal can be prolonged but less severe than with shorter-acting opioids.
- A 28-year-old woman with migraines takes sumatriptan during aura. The pain usually resolves within 30 min. Which downstream signaling event occurs after sumatriptan binds its vascular serotonin receptor?
Answer: Activation of Gi protein with decreased adenylate cyclase activity leading to vasoconstriction
When you encounter questions about migraine medications and their mechanisms, focus on the specific receptor subtypes and their associated signaling pathways. Sumatriptan is a selective 5-HT₁B/1D receptor agonist that provides rapid migraine relief through targeted vasoconstriction.
Sumatriptan binds to 5-HT₁B receptors on cranial blood vessels, which are coupled to Gi proteins. When activated, these Gi proteins inhibit adenylyl cyclase, reducing cyclic adenosine monophosphate (cAMP) levels. This decrease in cAMP leads to vasoconstriction of dilated cerebral vessels, which is the primary mechanism underlying sumatriptan's antimigraine effect. The vasoconstriction reduces the vascular component of migraine pain and explains the rapid onset you see clinically.
Looking at the incorrect options: Choice B describes a Gq-phospholipase C pathway leading to vasodilation, which is opposite to sumatriptan's vasoconstrictive action and involves different receptor coupling. Choice C mentions ATP-sensitive potassium channels and cGMP-mediated hyperpolarization, which describes mechanisms more typical of vasodilators like nitrates or certain antihypertensives. Choice D involves tyrosine kinase and MAP kinase phosphorylation driving smooth muscle growth, which describes long-term proliferative responses rather than the acute vasoconstriction needed for migraine relief.
For USMLE Step 1, remember that triptans (sumatriptan, rizatriptan, etc.) work through 5-HT₁B/1D receptors coupled to Gi proteins, causing vasoconstriction. This contrasts with many other vascular medications that cause vasodilation through different pathways. Understanding G-protein coupling patterns helps you quickly identify correct mechanisms.
- These adverse effects are caused by the drug's antagonist activity at which of the following receptors?
Answer: Muscarinic acetylcholine receptors
Amitriptyline is a tricyclic antidepressant (TCA) with strong anticholinergic properties. The symptoms described—dry mouth (xerostomia), urinary retention, constipation, and mydriasis (dilated pupils)—are classic signs of muscarinic receptor blockade. These effects result from the inhibition of parasympathetic nervous system activity throughout the body.
- A randomized trial compares two antipsychotic medications in treating acute mania. Drug X causes dose-dependent orthostatic hypotension, whereas Drug Y causes dose-dependent parkinsonism. MRI studies show that only Drug X significantly increases regional cerebral blood flow in the prefrontal cortex. The most likely difference in receptor-binding profiles between the two drugs is that Drug X has greater affinity for which receptor?
Answer: Serotonin 5-HT2A receptor on cortical pyramidal neurons regulating glutamate release
When evaluating antipsychotic medications, you need to connect clinical side effects with specific receptor mechanisms to understand their pharmacological profiles.
Drug X causes orthostatic hypotension and increases prefrontal cortical blood flow, while Drug Y causes parkinsonism. The key insight is that increased prefrontal blood flow suggests enhanced cortical activity, which occurs when serotonin 5-HT2A receptors are blocked. These receptors normally inhibit glutamate release from cortical pyramidal neurons. When Drug X blocks 5-HT2A receptors, it disinhibits glutamate release, increasing cortical activity and blood flow. This mechanism also explains the clinical benefits seen in treating negative symptoms of schizophrenia and cognitive enhancement.
Choice A is incorrect because α1-adrenergic blockade would cause the orthostatic hypotension but wouldn't specifically increase prefrontal cortical blood flow in the pattern described. Choice B represents the opposite of what's happening - Drug Y likely has greater D2 affinity, explaining its parkinsonian side effects through striatal dopamine blockade. Choice C is wrong because M4 muscarinic receptor differences wouldn't explain either the blood flow changes or the distinct side effect profiles described.
The correct answer is D. Drug X's greater 5-HT2A receptor affinity explains both its unique cerebral blood flow effects and suggests it's likely an atypical antipsychotic with fewer extrapyramidal side effects.
Study tip: Remember that 5-HT2A antagonism is a hallmark of atypical antipsychotics and explains their cognitive benefits and reduced extrapyramidal effects compared to typical antipsychotics that primarily block D2 receptors.
- A 68-year-old man with Parkinson disease is treated with carbidopa/levodopa, which markedly improves his bradykinesia and rigidity. After several months, he develops involuntary choreiform movements of the face and upper extremities that are most pronounced when the medication is at peak effect. Which of the following strategies is most appropriate to diminish these new symptoms while preserving control of his parkinsonian features?
Answer: Add amantadine to decrease dopaminergic dyskinesia through NMDA receptor antagonism
When you encounter a Parkinson's patient developing choreiform movements at peak medication effect, you're dealing with levodopa-induced dyskinesia (LID) - a common long-term complication of dopamine replacement therapy. The key is finding a treatment that reduces these involuntary movements without worsening the underlying parkinsonian symptoms.
Amantadine (A) is the correct choice because it uniquely addresses LID through NMDA receptor antagonism in the striatum. This mechanism helps normalize the abnormal glutamatergic signaling that contributes to dyskinesia, while preserving the beneficial dopaminergic effects for motor control. Clinical studies consistently show amantadine reduces dyskinesia severity without significantly worsening parkinsonism.
Benztropine (B) is an anticholinergic that helps with tremor and rigidity but doesn't address dyskinesia - in fact, it could worsen cognitive function in elderly patients. Increasing dosing frequency while reducing individual doses (C) might seem logical, but this approach often fails because it doesn't address the underlying sensitization that causes dyskinesia and may actually worsen it over time. Entacapone (D) increases levodopa bioavailability, which would likely exacerbate the dyskinesia since these movements occur at peak drug effect.
For USMLE Step 1, remember that levodopa-induced dyskinesia represents a "too much of a good thing" scenario - you need a medication that specifically targets the dyskinesia mechanism (glutamate/NMDA) rather than simply adjusting dopamine levels. Amantadine is the go-to anti-dyskinetic agent in clinical practice.
- The reduced efficacy of the local anesthetic in this setting is best explained by which of the following?
Answer: Inflamed tissue has a low extracellular pH, which increases the proportion of the cationic form of the drug.
Local anesthetics are weak bases. To be effective, they must cross the lipid-rich nerve membrane in their non-ionized (uncharged) form. Once inside the neuron, they re-equilibrate, and the ionized (cationic) form blocks the intracellular side of the voltage-gated sodium channel. Infected and inflamed tissues are acidic (have a low extracellular pH). This acidic environment protonates the weak base anesthetic, increasing the proportion of the ionized, cationic form. The charged form cannot effectively cross the nerve membrane, leading to reduced anesthetic efficacy.
- In utero exposure to valproic acid is most strongly associated with an increased risk for which of the following congenital malformations?
Answer: Neural tube defects
Valproic acid is a known human teratogen. Its use during the first trimester of pregnancy is associated with a significantly increased risk of major congenital malformations, most notably neural tube defects such as spina bifida. The mechanism is thought to involve inhibition of folate absorption and metabolism, which is critical for neural tube closure.
- This medication exerts its anxiolytic and adverse cognitive effects by which of the following mechanisms?
Answer: Increasing the frequency of chloride channel opening on the GABAA receptor
Lorazepam is a benzodiazepine. Benzodiazepines are positive allosteric modulators of the GABAA receptor. They bind to a site distinct from the GABA binding site and increase the frequency of chloride channel opening when GABA is bound. This enhances the inhibitory effect of GABA, leading to sedation, anxiolysis, and cognitive impairment, particularly in the elderly. Barbiturates increase the duration of channel opening.
- A 72-year-old man undergoes elective colonoscopy under monitored anesthesia care. He receives a rapid IV bolus of an anesthetic that produces immediate unconsciousness within 10 s and recovery of consciousness within 3 min. Which pharmacokinetic feature accounts for this drug's ultrashort duration of action?
Answer: Rapid redistribution from brain to skeletal muscle and adipose tissue after a single bolus
When you encounter questions about anesthetic drugs with ultrashort durations of action, think about what determines how quickly a drug effect ends after administration. The key is understanding that drug effect terminates when the drug leaves its site of action (the brain), which can happen through either elimination from the body or redistribution to other tissues.
The scenario describes propofol, which produces unconsciousness within seconds but wears off within minutes. This rapid onset and offset isn't due to the drug being eliminated from the body quickly—propofol actually has a long elimination half-life. Instead, the effect ends because propofol rapidly redistributes away from the brain to less perfused tissues like muscle and fat after the initial bolus. The brain receives the drug first due to its high blood flow, but as plasma levels drop, the drug quickly leaves the brain and moves to tissues with larger capacity but lower perfusion.
Choice A describes inhaled anesthetics like sevoflurane, not IV anesthetics like propofol. Choice B describes drugs like mivacurium or esmolol that are metabolized by plasma esterases—this isn't propofol's mechanism. Choice D suggests renal elimination, but propofol is primarily metabolized by the liver, and rapid renal secretion wouldn't account for the immediate offset described.
Remember this pattern: ultrashort-acting IV anesthetics (propofol, thiopental) terminate their effects through redistribution, not elimination. The drug doesn't disappear from the body quickly—it just moves away from the brain where it exerts its effect.
- What is the primary mechanism by which carbidopa enhances the therapeutic effect of levodopa and reduces its peripheral side effects?
Answer: It inhibits peripheral aromatic L-amino acid decarboxylase.
Carbidopa is an inhibitor of peripheral aromatic L-amino acid decarboxylase (also known as DOPA decarboxylase). This enzyme converts levodopa to dopamine. By inhibiting this enzyme in the periphery, carbidopa prevents the conversion of levodopa to dopamine outside the central nervous system. This increases the amount of levodopa that can cross the blood-brain barrier and be converted to dopamine in the brain, while reducing peripheral side effects like nausea, vomiting, and arrhythmias caused by peripheral dopamine.
- This patient's withdrawal syndrome is primarily caused by the downregulation of inhibitory neurotransmission and upregulation of excitatory neurotransmission. The acute symptoms are best explained by a sudden lack of ethanol-mediated potentiation of which receptor system?
Answer: GABAA receptors
Chronic ethanol use potentiates the effect of GABA at GABAA receptors, leading to increased chloride influx and CNS inhibition. To compensate, the body downregulates GABAA receptors. Concurrently, ethanol inhibits NMDA glutamate receptors, and the body compensates by upregulating them. Upon abrupt cessation of alcohol, the system is left in a hyperexcitable state: there is reduced GABAergic inhibition and excessive glutamatergic excitation, leading to the symptoms of alcohol withdrawal, including seizures and delirium tremens.
- A 46-year-old woman with refractory depression has tried multiple selective serotonin reuptake inhibitors without benefit. She is switched to phenelzine. One month later, she develops episodic headaches and palpitations after consuming aged cheese. Which intracellular change in peripheral vascular smooth muscle is primarily responsible for her acute hypertension?
Answer: Accumulation of diacylglycerol and inositol triphosphate after α1-adrenergic receptor stimulation
When you encounter a question about MAO inhibitors and food interactions, focus on the tyramine crisis mechanism and its downstream vascular effects.
This patient experienced a classic tyramine crisis. Phenelzine is a monoamine oxidase inhibitor (MAOI) that blocks the breakdown of tyramine from aged foods like cheese. The accumulated tyramine acts as an indirect sympathomimetic, displacing norepinephrine from nerve terminals and causing massive α1-adrenergic receptor stimulation in vascular smooth muscle.
Choice A is correct because α1-adrenergic receptor activation triggers the phospholipase C pathway, cleaving PIP₂ into diacylglycerol (DAG) and inositol triphosphate (IP₃). IP₃ releases calcium from the sarcoplasmic reticulum while DAG activates protein kinase C, both promoting smooth muscle contraction and vasoconstriction that causes the acute hypertension.
Choice B is wrong because presynaptic α2-autoreceptors normally provide negative feedback to limit norepinephrine release, but tyramine bypasses this mechanism by directly displacing stored norepinephrine. Additionally, decreased cAMP would reduce, not increase, vascular tone.
Choice C is wrong because increased cGMP and nitric oxide activity would cause vasodilation and hypotension, the opposite of what occurs in tyramine crisis.
Choice D is wrong because tyramine doesn't block ryanodine receptors. Instead, the α1-adrenergic stimulation increases intracellular calcium availability through IP₃-mediated release.
Study tip: Remember "MAOIs + aged foods = tyramine crisis = α1 stimulation = PLC pathway activation." This helps you connect the clinical scenario to the specific intracellular mechanism causing hypertension.
- A 55-year-old woman scheduled for craniotomy receives dexmedetomidine infusion for intraoperative sedation. Compared with benzodiazepine-based sedation, which physiologic effect is more characteristic of dexmedetomidine at clinically relevant doses?
Answer: Bradycardia and hypotension secondary to decreased sympathetic outflow from the locus coeruleus
When comparing sedative agents, focus on their distinct receptor mechanisms and resulting physiologic profiles. Dexmedetomidine is an α₂-adrenergic agonist, while benzodiazepines are GABA_A receptor positive allosteric modulators—these different targets produce markedly different effects.
Dexmedetomidine's primary action occurs at α₂-adrenoreceptors in the locus coeruleus, the brain's main noradrenergic nucleus. By binding these presynaptic receptors, dexmedetomidine inhibits norepinephrine release, dramatically reducing sympathetic nervous system outflow. This mechanism produces the characteristic hemodynamic effects: bradycardia (reduced heart rate) and hypotension (decreased blood pressure). These cardiovascular changes are dose-dependent and represent the drug's most distinguishing feature compared to benzodiazepines. Answer A correctly identifies this mechanism.
Answer B is incorrect because dexmedetomidine causes minimal respiratory depression—this is actually one of its major advantages over benzodiazepines and opioids. The drug doesn't significantly affect medullary respiratory centers or CO₂ sensitivity.
Answer C misrepresents dexmedetomidine's cerebral effects. The drug typically decreases intracranial pressure and has neuroprotective properties, making it favorable for neurosurgical procedures. It doesn't work through GABA_A potentiation.
Answer D describes the opposite of dexmedetomidine's effects. The drug produces anxiolysis and cooperative sedation without delirium. Paradoxical agitation is more associated with benzodiazepines, particularly in elderly patients.
Study tip: Remember "α₂ = sympathetic suppression." Dexmedetomidine's α₂-agonism equals decreased sympathetic tone, which equals bradycardia and hypotension—its signature effects distinguishing it from other sedatives.
- A 19-year-old college student is brought in for bizarre behavior. He is tachycardic, has vertical nystagmus, and is speaking incoherently while appearing indifferent to pain. The physician administers haloperidol IM, but the patient develops sudden generalized muscle rigidity and seizures. Which mechanism best explains why benzodiazepines are preferred over haloperidol in controlling agitation from this intoxication?
Answer: Allosteric potentiation of GABA_A chloride influx counteracts NMDA receptor blockade of the offending drug
When you encounter a case of intoxication with vertical nystagmus, dissociation, and analgesia, think PCP (phencyclidine) or ketamine. These are NMDA receptor antagonists that block glutamate transmission, leading to the characteristic dissociative symptoms.
The key insight here is understanding why haloperidol worsened this patient's condition. PCP intoxication already involves altered neurotransmitter balance due to NMDA blockade. When you add a dopamine D2 antagonist like haloperidol, you further disrupt the delicate balance between excitatory and inhibitory neurotransmission, potentially precipitating seizures and rigidity.
Answer A is correct because benzodiazepines work by enhancing GABA_A receptor function through allosteric potentiation, increasing chloride influx and neuronal inhibition. This helps counterbalance the excitatory effects caused by NMDA receptor blockade from PCP.
Answer B is wrong because while haloperidol does block D2 receptors, this mechanism actually caused the problem rather than solving it. The violent behavior isn't primarily from catecholamine surge.
Answer C is wrong because benzodiazepines don't work at σ-opioid receptors, and competitive antagonism isn't their mechanism of action.
Answer D is wrong because benzodiazepines aren't 5-HT1A partial agonists - that describes buspirone. PCP intoxication isn't primarily a serotonin problem.
Study tip: Remember that PCP/ketamine intoxication requires supportive care with benzodiazepines, not antipsychotics. Antipsychotics can worsen the neurological symptoms by further disrupting neurotransmitter balance.
- Osteomalacia during chronic phenytoin therapy is most directly due to:
Answer: Increased vitamin D catabolism
Chronic phenytoin induces hepatic cytochrome P450 enzymes, accelerating catabolism of vitamin D to inactive metabolites; low active vitamin D reduces calcium absorption and causes osteomalacia. The tempting wrong answer is dietary calcium deficiency, but phenytoin doesn't directly cause a deficient diet - it speeds vitamin D breakdown. Tubular phosphate wasting and decreased 1-alpha hydroxylase are not the primary mechanisms.
- Chronic levodopa therapy causes dyskinesias mainly because of:
Answer: Pulsatile dopamine stimulation
Levodopa has a short half-life, so each dose causes a spike and then a drop in brain dopamine, giving dopamine receptors pulsatile rather than steady stimulation. This intermittent pattern is what drives levodopa-induced dyskinesias. The tempting wrong answer is continuous dopamine action, but continuous receptor occupancy is actually the goal and does not cause the same complications.
- The rapid onset and recovery associated with this anesthetic agent are best explained by which of its physicochemical properties?
Answer: Low blood:gas partition coefficient
The speed of induction and recovery for an inhaled anesthetic is inversely proportional to its solubility in blood, which is measured by the blood:gas partition coefficient. Anesthetics with a low blood:gas partition coefficient (like desflurane and nitrous oxide) are less soluble in blood. This means that the partial pressure of the gas in the alveoli equilibrates very quickly with the partial pressure in the blood and brain, leading to rapid induction and rapid elimination upon discontinuation.
- Lithium is thought to produce both its therapeutic and certain adverse effects, such as nephrogenic diabetes insipidus, by interfering with which of the following signaling pathways?
Answer: Inositol phosphate signaling pathway
The proposed mechanism of action for lithium involves the inhibition of enzymes in the inositol phosphate signaling pathway, such as inositol monophosphatase. This depletes intracellular inositol, which dampens the signaling of Gq-protein coupled receptors, including certain adrenergic, muscarinic, and serotonergic receptors. Interference with this pathway in the renal collecting duct cells, specifically with the V2 receptor signaling for ADH, leads to nephrogenic diabetes insipidus, causing polyuria and polydipsia.
